Companies › Colgate Palmolive
8 active drug programs in 10 registered trials: 8 Phase 3, 2 Phase 4; Gastroenterology, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Test Mouthrinse Antimicrobial mouthrinse containing fluoride and zinc lactate for plaque reduction and gum | – | Phase 4 | Gingivitis | Nov 2026 |
| sodium monofluorophosphate toothpaste Fluoride source for dental remineralization and caries prevention | ENPP1 | Phase 4 | Gingivitis | – |
| Colgate SNaP Total 10/10, 1.5 Taurate Stannous fluoride toothpaste (0.454% SnF, 1100 ppm F) with taurate | UNKNOWN | Phase 3 | Plaque, Dental | Nov 2026 |
| 0.45% SnF HW with NaF (1450 F) Stannous fluoride with sodium fluoride for topical fluoride delivery and antimicrobial act | SLC5A1 | Phase 3 | Plaque | Jan 2027 |
| 67% Bicarbonate with NaF (1400 F) Sodium bicarbonate with sodium fluoride for plaque reduction | – | Phase 3 | Plaque | Jan 2027 |
| 0.412% stannous fluoride toothpaste Topical fluoride and tin for plaque and gingivitis reduction | – | Phase 3 | Plaque | Apr 2027 |
| 8% arginine + Zinc toothpaste Dentin occluding agent containing arginine and zinc phosphate | – | Phase 3 | Dentinal Sensitivity | – |
| Max Fresh Toothpaste zinc citrate for oral malodor reduction | – | Phase 3 | Oral Malodor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07398378 | Max Fresh Toothpaste | Phase 3 | Oral Malodor | Other | Jul 2026 |
| NCT07664592 | 8% arginine + Zinc toothpaste | Phase 3 | Dentinal Sensitivity | Gastroenterology | Sep 2026 |
| NCT07664592 | 8% arginine + Zinc toothpaste | Phase 3 | Dentinal Sensitivity | Gastroenterology | Sep 2026 |
| NCT07664592 | 8% arginine + Zinc toothpaste | Phase 3 | Dentinal Sensitivity | Gastroenterology | Sep 2026 |
| NCT07614490 | sodium monofluorophosphate toothpaste | Phase 4 | Gingivitis | Gastroenterology | Sep 2026 |
| NCT07414173 | Test Mouthrinse | Phase 4 | Gingivitis | Gastroenterology | Nov 2026 |
| NCT07605338 | Colgate SNaP Total 10/10, 1.5 Taurate | Phase 3 | Plaque, Dental | Gastroenterology | Nov 2026 |
| NCT07842991 | 0.45% SnF HW with NaF (1450 F) | Phase 3 | Plaque | Gastroenterology | Jan 2027 |
| NCT07842991 | 67% Bicarbonate with NaF (1400 F) | Phase 3 | Plaque | Gastroenterology | Jan 2027 |
| NCT07917507 | 0.412% stannous fluoride toothpaste | Phase 3 | Plaque | Gastroenterology | Apr 2027 |
Cash of $1.5bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Procter and Gamble Norgine Elgan Pharma Cinclus Pharma Holding Polaris Group
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.